# Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment

> **NCT02261636** · — · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 150 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** mesalazine

## Key facts

- **NCT ID:** NCT02261636
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2019-01-14
- **Final completion:** 2019-01-14
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2022-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02261636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02261636, "Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02261636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*